Harbor Investment Advisory, LLC Apellis Pharmaceuticals, Inc. Transaction History

Harbor Investment Advisory, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 14, 2023	SELL	$76.68 - $93.31 $51,068 - $62,144	-666 Reduced 49.96%	667 $60,000
Q2 2022 Jul 18, 2022	BUY	$35.07 - $59.21 $7,715 - $13,026	220 Added 19.77%	1,333 $60,000
Q1 2022 Apr 20, 2022	SELL	$35.46 - $54.12 $5,460 - $8,334	-154 Reduced 12.15%	1,113 $57,000
Q4 2021 Jan 10, 2022	BUY	$30.74 - $49.16 $7,807 - $12,486	254 Added 25.07%	1,267 $60,000
Q3 2021 Oct 12, 2021	BUY	$31.4 - $69.84 $16,893 - $37,573	538 Added 113.26%	1,013 $33,000
Q2 2021 Jul 27, 2021	BUY	$40.9 - $64.9 $19,427 - $30,827	475 New	475 $30,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Harbor Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Harbor Investment Advisory, LLC with notifications on news.